Lunesta
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Poor Quality Sleep
Conditions
Poor Quality Sleep
Trial Timeline
Jun 1, 2005 → Dec 1, 2010
NCT ID
NCT00460993About Lunesta
Lunesta is a approved stage product being developed by Sumitomo Pharma for Poor Quality Sleep. The current trial status is completed. This product is registered under clinical trial identifier NCT00460993. Target conditions include Poor Quality Sleep.
What happened to similar drugs?
2 of 2 similar drugs in Poor Quality Sleep were approved
Approved (2) Terminated (1) Active (0)
✅Cultured Thymus Tissue + Rabbit Anti-Thymocyte Globulin and Cyclosporine or TacrolimusSumitomo PharmaApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00460993 | Approved | Completed |
Competing Products
7 competing products in Poor Quality Sleep
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Bocidelpar + Placebo | Astellas Pharma | Phase 1 | 21 |
| Cultured Thymus Tissue + Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus | Sumitomo Pharma | Approved | 43 |
| Rosuvastatin Calcium | AstraZeneca | Phase 1 | 29 |
| Lutropin alfa + Follitropin alfa | Merck | Approved | 35 |
| Eltrombopag | Novartis | Phase 2 | 27 |
| Everolimus (Afinitor®) | Novartis | Phase 2 | 35 |
| Cabozantinib S-malate | Exelixis | Phase 2 | 32 |